Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…
Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…
Dr Reddy's Laboratories Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain the situation there and what measures did you take to turn the situation around? Germany, and in particular the Betapharm…
India Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in the rankings. How satisfied are you with the company’s performance in 2010? The company performed satisfactorily last year, showing good…
Gedeon Richter Czech Republic Mr. Gyürüsi, Gedeon Richter is a 111-year-old company that is synonymous with the Central and Eastern European pharma industry. The business has been present in Czechoslovakia since 1956, and has acted independently in the Czech Republic since 1992. Can you give our readers a more detailed idea of the history…
Genzyme Poland With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market, in bio-surgery, in oncology, and also in transplant. What area has been driving the growth in 2010? In value terms,…
Novartis Argentina When we met with Javier Lombar at IMS Argentina, he was explaining how a lot of multinational companies are using Argentina as a regional base of operations. Novartis is a prime example of this. Could you explain how Novartis operates in a Latin American context, and what role the Argentinean…
Gelpharma Gelpharma started in 1999 and its main strength lies in manufacturing. Please can you give us a more detailed history of the company and its major milestones since opening? We started over forty years ago from a company called Vitae Laboratorios that for many years had two soft-gel products manufactured…
Boehringer Ingelheim Mexico You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time? I’ve been in the company for 18 years, and came back from Germany in 2010 to become the company’s first…
Cegedim Mexico From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over the last few years? One of the most important issues that changed in the Mexican pharmaceutical industry is the growth of generics, and this…
Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…
See our Cookie Privacy Policy Here
